FATE THERAPEUTICS INC
Datakwaliteit: 100%
FATE
NASDAQ
Manufacturing
Chemicals
€ 1,28
▼
€ 0,06
(-4,48%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-41,27%
Groei
Revenue Growth (5Y)
-41,27%
Onder sectorgemiddelde (1,72%)
Revenue (1Y)-51,24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-55,03%
Onder sectorgemiddelde (-54,47%)
ROIC-35,44%
Net Margin-2051,08%
Op. Margin-2222,45%
Veiligheid
Debt / Equity
N/A
Current Ratio7,87
Interest CoverageN/A
Waardering
PE (TTM|NTM)
-1,08 | -1,18
Boven sectorgemiddelde (-1,50)
P/B Ratio0,63
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -41,27% annually over 5 years
Negative free cash flow of -112,04 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 9,97%
Capital intensive — 89,57% of revenue goes to capex
Price History
Financiële Trends
Koersdoel Analisten
9 analisten
Buy
+286.3%
upside to target
Huidig
€ 1,28
Consensus Target
€ 4,94
€ 2,00
Laag
€ 8,00
Hoog
Vooruitzicht
Forward K/W
-1,18
Forward WPA
-€ 1,05
Omzet Sch.
5,79 M
Winstverassingen
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -€ 0,28
·
Rev Est: 1,26 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -€ 0,32 | -€ 0,29 | -€ 0,27 | -€ 0,27 | — | — |
| Estimate | -€ 0,38 | -€ 0,34 | -€ 0,28 | -€ 0,27 | -€ 0,28 | -€ 0,29 |
| Verrassing | +15,66% | +15,76% | +4,33% | +0,46% | — | — |
Growth
Rev 5Y: -41,27% · Earnings 1Y: N/A
Growth
Rev 5Y: -41,27% · Earnings 1Y: N/A| Revenue Growth (1Y) | -51,24% | Revenue Growth (3Y) | -67,66% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -41,27% | Earnings Growth (5Y) | N/A |
Profitability
ROE: -55,03% · Net Margin: -2051,08%
Profitability
ROE: -55,03% · Net Margin: -2051,08%| Revenue (TTM) | 6,65 M | Net Income (TTM) | -136,32 M |
| ROE | -55,03% | ROA | -38,11% |
| Gross Margin | N/A | Operating Margin | -2222,45% |
| Net Margin | -2051,08% | Free Cash Flow (TTM) | -112,04 M |
| ROIC | -35,44% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 7,87
Safety
D/E: N/A · Current: 7,87| Debt / Equity | N/A | Current Ratio | 7,87 |
| Interest Coverage | N/A | Asset Turnover | 0,02 |
| Working Capital | 193,14 M | Tangible Book Value | 234,07 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -1,08 · EV/EBITDA: N/A
Valuation
P/E: -1,08 · EV/EBITDA: N/A| P/E Ratio | -1,08 | Forward P/E | -1,18 |
| P/B Ratio | 0,63 | P/S Ratio | 22,22 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 25,49 | Fwd Earnings Yield | N/A |
| FCF Yield | -75,88% | ||
| Market Cap | 147,65 M | Enterprise Value | 107,03 M |
Per Share
EPS: -1,15 · FCF/Share: -0,96
Per Share
EPS: -1,15 · FCF/Share: -0,96| EPS (Diluted TTM) | -1,15 | Revenue / Share | 0,06 |
| FCF / Share | -0,96 | OCF / Share | -0,91 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 82,19% · CapEx/Rev: 89,57%
Efficiency
FCF Conv: 82,19% · CapEx/Rev: 89,57%| CapEx / Revenue | 89,57% | FCF Conversion | 82,19% |
| SBC-Adj. FCF | N/A | Growth Momentum | -9,97 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6,65 M | 13,63 M | 63,53 M | 96,30 M | 55,85 M |
| Net Income | -136,32 M | -186,26 M | -160,93 M | -281,72 M | -212,15 M |
| EPS (Diluted) | -1,15 | -1,64 | -1,64 | -2,91 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -147,70 M | -210,28 M | -190,51 M | -308,39 M | -216,99 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 107,83 M | 135,00 M | 172,60 M | 320,45 M | 215,52 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 12,90 M | 18,96 M | 18,28 M | 13,76 M | 5,85 M |
| Interest Expense | — | — | — | — | 0,0 |
| Income Tax | 2.000,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 318,94 M | 440,69 M | 506,22 M | 705,56 M | 921,46 M |
| Total Liabilities | — | — | — | — | — |
| Shareholders' Equity | 207,18 M | 318,73 M | 368,42 M | 483,94 M | 678,84 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 46,63 M | 36,06 M | 41,87 M | 61,33 M | 133,58 M |
| Current Assets | 208,70 M | 291,91 M | 331,54 M | 502,07 M | 633,41 M |
| Current Liabilities | 36,07 M | 38,52 M | 39,09 M | 114,05 M | 81,28 M |
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers)
Vergeleken met vergelijkbare bedrijven in Manufacturing
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers) Vergeleken met vergelijkbare bedrijven in Manufacturing| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,1 | -1,5 |
| P/B | 0,6 | 1,6 |
| ROE % | -55,0 | -54,5 |
| Net Margin % | -2051,1 | -41,5 |
| Rev Growth 5Y % | -41,3 | 1,7 |
| D/E | — | 0,3 |
{"event":"ticker_viewed","properties":{"ticker":"FATE","listing_kind":"stock","pathname":"/stocks/fate","exchange":"NASDAQ","country":"US"}}